Gene therapy approaches for malignant brain tumors evolved from the need to develop new treatment modalities, increasing insights in the molecular basis of tumorigenesis and the advent of recombinant DNA technology. Immunotherapy of tumors growing in an immunologically privileged organ is a challeng ing task for researchers and clinicians. Both strategies, systemic immunization and local overexpression of cytokines in the brain tumor, have been successfully applied to experimental tumor models. The first clinical gene immunotherapy trials of malignant gliomas uses a vaccine consisting of tumor cells and fibro-blasts genetically modified to express interleukin-2. Chemotherapy of brain tumors is based on the conversion of relatively nontoxic prodrugs into cytotoxic chemotherapeutic agents by suicide genes. Cytosine deaminase from E. coli and thymidine kinase from herpes simplex virus confer lethal cytotoxicity to cells expressing either one of the suicide genes in the presence of the appropriate prodrug 5-fluorocytosine or ganciclovir. Several gene therapy trials have been approved for the treatment of malignant brain tumors with herpes simplex thymidine kinase and ganciclovir. Insights in the molecular basis of tumorigenesis stimulated therapy approaches for restoration of cell cycle gene functions and growth control in malignant tumor cells. Introduction of wild-type p53 tumor suppressor gene into tumor cells lacking the normal protein has not only been shown to revert the malignant phenotype, but also to induce apoptosis in response to DNA damaging by conventional chemotherapy and radiotherapy treatment. These findings are now being translated into clinical gene transfer trials.

Keywords:
Gene therapy: malignant glioma
This content is only available via PDF.
© 1996 S. Karger AG, Basel
1996
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.